Details for Patent: 8,853,397

Title:	2,4-pyrimidinediamine compounds and their uses
Abstract:	The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Inventor(s):	Singh; Rajinder (Belmont, CA), Argade; Ankush (Foster City, CA), Payan; Donald G. (Hillsborough, CA), Molineaux; Susan (San Mateo, CA), Holland; Sacha J. (San Francisco, CA), Clough; Jeffrey (Redwood City, CA), Keim; Holger (Irvine, CA), Bhamidipati; Somasekhar (Foster City, CA), Sylvain; Catherine (Burlingame, CA), Li; Hui (Santa Clara, CA), Rossi; Alexander B. (San Francisco, CA)
Assignee:	Rigel Pharmacuticals, Inc. (South San Francisco, CA)
Filing Date:	Feb 05, 2013
Application Number:	13/759,835
Claims:	1. A compound according to Formula (I) ##STR00048## or a salt thereof, wherein: one of R.sup.2 and R.sup.4 is a phenyl monosubstituted with (C1-C10)alkyl, --OR.sup.a optionally substituted with one R.sup.b group, --O--C(O)OR.sup.a, --O--(CH.sub.2).sub.m--C(O)OR.sup.a, --C(O)OR.sup.a, --O--(CH.sub.2).sub.m--NR.sup.cR.sup.c, --O--C(O)NR.sup.cR.sup.c, --O--(CH.sub.2).sub.m--C(O)NR.sup.cR.sup.c, --O--C(NH)NR.sup.cR.sup.c, --O--(CH.sub.2).sub.m--C(NH)NR.sup.cR.sup.c or --NH--(CH.sub.2).sub.mNR.sup.cR.sup.c; the other of R.sup.2 and R.sup.4 is a phenyl monosubstituted or disubstituted with R.sup.8; R.sup.2 and R.sup.4 are different; R.sup.5 is --NR.sup.cR.sup.c, fluoro, --CN, or (C1-C6) alkyl optionally substituted with one or more of the same or different R.sup.8 groups; each R.sup.8 is independently R.sup.a or R.sup.b; each R.sup.a is H or (C1-C6) alkyl; each R.sup.b is --OR.sup.a, --OCF.sub.3, halogen, --CF.sub.3, --CN, --NO.sub.2, --N.sub.3, --SO.sub.2NR.sup.cR.sup.c, --C(O)R.sup.a, --C(O)OR.sup.a, --C(O)NR.sup.cR.sup.c, --C(NH)NR.sup.cR.sup.c, --C(NR.sup.a)NR.sup.cR.sup.c, --C(NOH)R.sup.a, --C(NOH)NR.sup.cR.sup.c; each R.sup.c is independently R.sup.a or, alternatively, two R.sup.c are taken together with the nitrogen atom to which they are bonded to form a 5- to 8-membered cycloheteroalkyl or heteroaryl; and each m is independently 1 or 2. 2. The compound of claim 1, wherein R.sup.5 is fluoro or (C1-C4) alkanyl optionally substituted with one or more of the same or different R.sup.8 groups. 3. The compound of claim 2, wherein each R.sup.b is independently --OR.sup.a, --OCF.sub.3, halogen, --CF.sub.3, --CN, --NO.sub.2, --N.sub.3, --SO.sub.2NR.sup.cR.sup.c, --C(O)R.sup.a, --C(O)OR.sup.a or --C(O)NR.sup.cR.sup.c. 4. The compound of claim 3, wherein R.sup.5 is fluoro or --CF.sub.3. 5. The compound of claim 4, wherein each m is 1. 6. The compound of claim 5, wherein R.sup.5 is fluoro. 7. The compound of claim 1, wherein R.sup.2 is phenyl monosubstituted with --O--(CH.sub.2).sub.m--NR.sup.cR.sup.c.